162 related articles for article (PubMed ID: 38573832)
1. Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.
Sun L; He M; Li F; Wu D; Zheng P; Zhang C; Liu Y; Liu D; Shan M; Yang M; Ma Y; Lian J; Xiong H
Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38573832
[TBL] [Abstract][Full Text] [Related]
2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
3. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
[TBL] [Abstract][Full Text] [Related]
4. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
5. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
[No Abstract] [Full Text] [Related]
6. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
7. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
8. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
10. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
12. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
[TBL] [Abstract][Full Text] [Related]
13. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
15. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
16. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
17. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
Guo XL; Wang HB; Yong JK; Zhong J; Li QH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839
[TBL] [Abstract][Full Text] [Related]
18. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
19. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
[TBL] [Abstract][Full Text] [Related]
20. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]